MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Status:
Not yet recruiting
Trial end date:
2026-05-15
Target enrollment:
Participant gender:
Summary
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated
extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of
binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor
types In this Phase II, the drug will be used to treat pediatric patients diagnosed with
recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery
and/or radiation therapy.